---
title: Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
date: '2024-10-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39383459/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241009193150&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: At a median follow-up of 6 years after lentiviral gene
  therapy, most patients with early cerebral adrenoleukodystrophy and MRI abnormalities
  had no major functional disabilities. However, insertional oncogenesis is an ongoing
  risk associated with the integration of viral vectors. (Funded by Bluebird Bio;
  ALD-102 and LTF-304 ClinicalTrials.gov numbers NCT01896102 and NCT02698579, ...'
disable_comments: true
---
CONCLUSIONS: At a median follow-up of 6 years after lentiviral gene therapy, most patients with early cerebral adrenoleukodystrophy and MRI abnormalities had no major functional disabilities. However, insertional oncogenesis is an ongoing risk associated with the integration of viral vectors. (Funded by Bluebird Bio; ALD-102 and LTF-304 ClinicalTrials.gov numbers NCT01896102 and NCT02698579, ...